id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-312875-gn6hg6oc	Infante, Marco	Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID‐19 pandemic	2020-05-13		.txt	text/plain	4839	291	43	(3) Although the exact mechanisms of action underlying the glucose-lowering properties of HCQ are still not entirely clear and may differ between patients with and without diabetes, pre-clinical and clinical data suggest that HCQ could exert multifaceted effects on glucose homeostasis, namely: improvement of insulin sensitivity, increase of insulin secretion, reduction of hepatic insulin clearance and intracellular insulin and insulin-receptor complex degradation, increase of adiponectin levels, reduction of systemic inflammation, and/or reduction of inflammation-induced insulin resistance in adipocytes and skeletal muscle cells. (13) More recently, a 24-week prospective randomized trial (14) and two real-world, prospective observational studies of short duration (up to 24-48 weeks) (5, 15) conducted in India have shown that the use of HCQ (400 mg/day) as an add-on treatment in patients with T2D uncontrolled on a combination of two or more oral hypoglycemic agents (including metformin, sulfonylureas, pioglitazone, DPP-4 inhibitors, SGLT2 inhibitors, and alpha-glucosidase inhibitors) was welltolerated and led to a significant improvement of glucose control (assessed by HbA1c, fasting-and postprandial blood glucose) from baseline (without occurrence of severe hypoglycemia).	./cache/cord-312875-gn6hg6oc.txt	./txt/cord-312875-gn6hg6oc.txt